Resperate is a non-pharmacological treatment option for the management of hypertension; it is classed as a device and is the first to be available on NHS prescription. The device can be recommended as an option in patients who:
- are aged over 65 years who remain hypertensive despite appropriate antihypertensive medication;
- have diabetes;
- are diagnosed with isolated systolic hypertension or refractory hypertension;
- refuse medication; or
- experience side effects.
How it works
Resperate consists of a monitor with headphones and an attached breathing sensor. The sensor is placed on the upper abdomen to automatically analyse the patient’s breathing pattern. The patient then listens to the personalised programme of distinct inhale and exhale tones generated by the breathing sensor according to their breathing pattern. As a result, sympathetic neural activity is reduced, decreasing peripheral resistance in small blood vessels and lowering blood pressure.
The device should be used routinely for 15 minutes a day and there are no known contraindications or side effects related to Resperate. In clinical trials, most patients saw a clinically significant reduction in blood pressure after 3—4 weeks and further reductions accumulated with consistent use.